Pharmacogenetics in Child and Adolescent Psychiatry: Background and Evidence-Based Clinical Applications

被引:1
|
作者
Malik, Salma [1 ,2 ]
Verma, Pragya [2 ]
Ruano, Gualberto [1 ]
Al Siaghy, Areej [2 ]
Dilawar, Azwa [3 ]
Bishop, Jeffrey R. [4 ,5 ]
Strawn, Jeffrey R. [6 ]
Namerow, Lisa B. [1 ]
机构
[1] Univ Connecticut, Sch Med, Dept Psychiat, Farmington, CT USA
[2] Hartford Hosp, Inst Living, Div Child & Adolescent Psychiat, 200 Retreat Ave, Hartford, CT 06019 USA
[3] Weill Cornell Med Sch, Doha, Qatar
[4] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN USA
[5] Univ Minnesota, Med Sch, Dept Psychiat, Minneapolis, MN USA
[6] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA
基金
美国国家卫生研究院;
关键词
pharmacogenetic testing; CPIC; DPWG; FDA; pharmacokinetic; pharmacodynamic; CONSORTIUM CPIC GUIDELINE; DRUG-METABOLIZING-ENZYMES; MAJOR DEPRESSIVE DISORDER; IMPLEMENTATION CONSORTIUM; GENOTYPE; RECOMMENDATIONS; CARBAMAZEPINE; SELECTION; HEALTH; IMPACT;
D O I
10.1089/cap.2023.0074
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The efficacy and tolerability of psychotropic medications can vary significantly among children and adolescents, and some of this variability relates to pharmacogenetic factors. Pharmacogenetics (PGx) in child and adolescent psychiatry can potentially improve treatment outcomes and minimize adverse drug reactions. This article reviews key pharmacokinetic and pharmacodynamic genes and principles of pharmacogenetic testing and discusses the evidence base for clinical decision-making concerning PGx testing. This article reviews current guidelines from the United States Food and Drug Administration (FDA), the Clinical Pharmacogenetics Implementation Consortium (CPIC), and the Dutch Pharmacogenetics Working Group (DPWG) and explores potential future directions. This review discusses key clinical considerations for clinicians prescribing psychotropic medications in children and adolescents, focusing on antidepressants, antipsychotics, stimulants, norepinephrine reuptake inhibitors, and alpha-2 agonists. Finally, this review synthesizes the practical use of pharmacogenetic testing and clinical decision support systems.
引用
收藏
页码:4 / 20
页数:17
相关论文
共 50 条